For U.S. Healthcare Professionals

Questions? Call 855-4ADYNOVATE

Stay Updated

RECONSTITUTION

BAXJECT III Reconstitution System1

BAXJECT III Reconstitution System

BAXJECT III Reconstitution System Demonstration Video

For detailed step-by-step instructions for reconstituting ADYNOVATE with the BAXJECT III Reconstitution System, watch the video below or download the Instructions for Use.

Infusion Information for ADYNOVATE

Patients should be trained on how to do infusions by their healthcare provider or hemophilia treatment center.

BAXJECT III Reconstitution System Troubleshooting Video

To learn how to recover ADYNOVATE if the initial reconstitution procedure fails, watch the video below.

BAXJECT III Reconstitution System Product Information

For complete instructions for use please refer to the ADYNOVATE full Prescribing Information.

  • Easy one-step activation for reconstituting ADYNOVATE in a BAXJECT III system1
  • Eliminates the need to disinfect, as vials are already assembled in the system housing1
    • Always ensure you work on a clean surface and wash your hands before reconstituting
  • Straightforward pooling process if more than 1 vial is needed—all ADYNOVATE can be drawn into the same syringe1
Detailed Important Risk Information
Prescribing Information (PI)
ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] Important Information
Indications

ADYNOVATE, Antihemophilic Factor (Recombinant), PEGylated, is a human antihemophilic factor indicated in children and adults with hemophilia A (congenital factor VIII deficiency) for:

  • On-demand treatment and control of bleeding episodes
  • Perioperative management
  • Routine prophylaxis to reduce the frequency of bleeding episodes

Limitation of Use

ADYNOVATE is not indicated for the treatment of von Willebrand disease.

DETAILED IMPORTANT RISK INFORMATION


Click here for ADYNOVATE full Prescribing Information.



ADVATE [Antihemophilic Factor (Recombinant)] Important Information
Indications

ADVATE is a recombinant antihemophilic factor indicated for use in children and adults with hemophilia A (congenital factor VIII deficiency) for:

  • Control and prevention of bleeding episodes.
  • Perioperative management.
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

ADVATE is not indicated for the treatment of von Willebrand disease.

DETAILED IMPORTANT RISK INFORMATION

Neutralizing Antibodies
Neutralizing antibodies (inhibitors) have been reported following administration of ADVATE predominantly in previously untreated patients (PUPs) and previously minimally treated patients (MTPs). Monitor all patients for the development of factor VIII inhibitors by appropriate clinical observation and laboratory testing. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an expected dose, perform an assay that measures factor VIII inhibitor concentration.

Click here for ADVATE full Prescribing Information.